Coherus BioSciences: A High-Stakes Pivot from Biosimilars to Immuno-Oncology with Boom-or-Bust Potential
Coherus BioSciences (rebranded as Coherus Oncology, Inc.) is a biopharmaceutical company that has recently transformed its focus from biosimilar drugs to novel immuno-oncology therapiesquantisnow.com. Founded in 2010, Coherus initially built a portfolio of biosimilars – notably UDENYCA® (pegfilgrastim-cbqv, a Neulasta biosimilar) for neutropenia and CIMERLI® (ranibizumab-eqrn, a Lucentis biosimilar) for retinal diseases – which drove its revenues through 2023sec.gov. In 2023-2024 the company pivoted strategically: it divested its ophthalmology franchise (Cimerli) to Sandoz in early 2024sec.gov and agreed to sell the Udenyca franchise in 2025, effectively exiting the biosimilar businessstevewagsinvest.com. Today, Coherus is positioned as an oncology-focused company with one marketed immunotherapy, LOQTORZI™ (toripalimab-tpzi), a next-generation PD-1 inhibitor for nasopharyngeal carcinoma (NPC)sec.gov. It is developing a pipeline of innovative cancer immunotherapies – including novel antibodies targeting IL-27 and CCR8 – intended to complement its PD-1 agentquantisnow.comquantisnow.com. Coherus’s key market segments now center on oncology: head & neck cancers (with NPC as an initial niche), and broader solid tumor immunotherapy opportunities via combination treatments, departing from its legacy segments in supportive care and ophthalmology. In summary, Coherus is at a critical inflection point – transforming from a biosimilar revenue base to a high-risk, high-reward immuno-oncology play.
Revenue Drivers: Until 2023, Coherus’s revenues were driven almost entirely by its biosimilars. UDENYCA (a long-acting G-CSF for chemotherapy-induced neutropenia) was the flagship product, contributing $127.1 million in sales in FY2023sec.gov. CIMERLI (for wet AMD and retinal disorders) quickly ramped to $125.4 million in FY2023sec.gov, reflecting strong uptake as the first and only FDA-interchangeable biosimilar of Lucentis. However, these legacy drivers have been monetized and removed from ongoing operations via divestitures. In April 2025 Coherus sold the Udenyca franchise to Intas Pharmaceuticals for up to $558 million (including $483 million upfront cash)stevewagsinvest.com, following the March 2024 sale of Cimerli to Sandoz for ~$170 millionsec.gov. With the biosimilar unit effectively wound down, current revenues are derived from LOQTORZI (toripalimab), launched in the U.S. for NPC in Q1 2024sec.gov. In its first full quarter on market, Loqtorzi generated $7.3 million net sales (Q1 2025) and drove total continuing revenues of ~$7.6 million, up from just $2.3 million a year prior (when only a Humira biosimilar contributed minimally)stevewagsinvest.com. Going forward, Loqtorzi’s uptake in the ultra-niche NPC population is the primary revenue driver in the near term. Management has guided to $40–50 million in Loqtorzi sales in 2025, aiming for a long-term peak of $150–200 million annuallyquantisnow.comquantisnow.com, which indicates expectations of broader usage (potentially from expanded indications or combination regimens).
Growth Initiatives: Coherus’s growth strategy hinges on developing and commercializing novel cancer therapies. Having built a “fully integrated” commercial infrastructure through its biosimilar business, Coherus is leveraging this platform to market Loqtorzi and future oncology productsquantisnow.com. Key initiatives include: (1) Expanding Loqtorzi’s adoption – by educating oncologists on its category-1 NCCN guideline endorsement for NPC (the only preferred immunotherapy in first-line and subsequent-line NPC)sec.gov, and securing broad payer coverage (which has already been confirmed across Medicare and major commercial plans)sec.gov. Early demand for Loqtorzi is tracking to expectations, with dozens of treatment centers already ordering within weeks of launchsec.gov. (2) Advancing the Immuno-Oncology Pipeline – Coherus is developing combination therapies to enhance PD-1 efficacy. Lead pipeline assets include CHS-114 (an anti-CCR8 “Treg-depleting” antibody) and casdozokitug (formerly SRF-388, an anti-IL-27 cytokine antagonist). Both are in Phase 1/2 trials and showed promising early data: CHS-114 demonstrated proof-of-mechanism with partial responses in PD-1–refractory head & neck cancer when combined with toripalimabstevewagsinvest.comstevewagsinvest.com, and casdozokitug combined with checkpoint inhibitors improved response rates in a Phase 2 liver cancer studystevewagsinvest.comstevewagsinvest.com. Coherus plans to initiate expansion cohorts and Phase 2 trials for these combos in 2025–2026, aiming to unlock new indications (e.g. second-line head & neck, gastric cancer, hepatocellular carcinoma)stevewagsinvest.com. (3) Lifecycle Management & Partnerships: The company is also exploring synergistic combinations such as a partnered Phase 3 trial with INOVIO’s immunotherapy in HPV+ throat cancersec.gov. Coherus’s strategy is to focus its resources on oncology – as evidenced by a 30% workforce reduction in 2024 and reallocation of capital from divested products into R&Dsec.govsec.gov. This sharper focus, backed by substantial cash infusions from asset sales, is intended to drive a pipeline-led growth trajectory over the coming years.
Competitive Advantages: In its new incarnation, Coherus is positioning itself as a nimble immunotherapy player with a fast-follower approach. One advantage is its commercial expertise in oncology clinics: Coherus established strong relationships and distribution channels selling Udenyca to oncology practices (where pegfilgrastim is used), and it can leverage these relationships for Loqtorzi and future oncology products. For example, at launch Coherus quickly achieved formulary acceptance for Loqtorzi, aided by its Category 1 guideline statussec.gov – a status that should ease reimbursement and adoption. Another edge is first-to-market status in NPC: Toripalimab (Loqtorzi) is the first and only FDA-approved therapy specifically for nasopharyngeal carcinoma across all linessec.gov. Given NPC is rare (especially in the West), major competitors (Keytruda, Opdivo) have not focused on this indication; Coherus faces little direct competition in NPC and effectively sets a new standard of care, which it can capitalize on as the sole supplier. Additionally, Coherus’s biosimilar background fostered a corporate culture of cost discipline and pricing flexibility. The company aggressively priced its biosimilars (e.g. YUSIMRY™, its Humira biosimilar, launched at a steep discount) to win share. We may see a similar strategy in immuno-oncology: for instance, Coherus could price toripalimab competitively against bigger PD-1 drugs if pursuing broader indications, or use flexible contracting to penetrate markets. Finally, Coherus’s pipeline targets (CCR8, IL-27) represent novel biology firsts in immunotherapy, potentially giving it a technology edge if these mechanisms prove effective. Early data linking biomarker-driven responses to IL-27 blockadesec.gov suggest Coherus might carve out unique combination regimens that larger immunotherapy companies have not explored deeply. In summary, Coherus’s competitive strengths lie in its oncology commercial know-how, its beachhead in an underserved cancer niche, and a cash-rich balance sheet to fund innovative combination trials. These advantages, however, must be weighed against formidable competition from established oncology players and the company’s lack of a broad marketed portfolio post-pivot.
Recent Financial Performance (2024–2025): Coherus’s financials reflect its transitional state. Full-year 2023 revenue was $257.2 million, up modestly from 2022, driven by Udenyca and Cimerli salessec.gov. However, heavy R&D investments in its immuno-oncology pipeline and one-time licensing costs (e.g. a $35 million Junshi license fee) yielded a sizeable net loss of $(237.9) million in 2023 (GAAP)sec.gov. Notably, the 2023 loss was narrower than 2022’s $(291.8) million loss, thanks to cost controls and winding down some biosimilar development expensessec.govsec.gov. By Q1 2024, the company began divesting assets: it sold the Cimerli ophthalmology business in March 2024 for $170 million cash and used $175 million of cash to pay down debt, cutting its term loan balance from $250M to $75Msec.gov. This move reduced annual interest expense by ~70%sec.gov and lowered ongoing SG&A associated with that franchise.
As Coherus entered 2024-2025, reported revenues have declined with the exit of major products. In Q4 2023, net sales were $91.5Msec.gov; by Q1 2025, net sales from continuing operations were a mere $7.6 million (all from Loqtorzi), since Udenyca’s $31.5M of sales were classified as discontinued operations pending its salestevewagsinvest.comstevewagsinvest.com. The company’s last quarter with Udenyca (Q1 2025) still showed that biosimilar contributing ~$31M despite a supply interruption in late 2024stevewagsinvest.com, indicating the underlying demand remained solid. But with Udenyca now sold (as of April 2025), Coherus’s going-forward revenue base is very small. For full-year 2024, we can infer a significant drop in revenue from 2023, partially offset by initial Loqtorzi sales and possibly a few million from Yusimry (Humira biosimilar) before that too was deemphasized. Importantly, Coherus’s cost structure is being right-sized for its new model: management initiated a 30% workforce reduction and guided 2024 operating expenses (R&D + SG&A) to $250–265M, down >12% from 2023sec.govsec.gov. Q1 2025 results show these efforts bearing fruit – continuing ops net loss was $47.4M (or $0.41/share) in Q1 2025, significantly narrower than the $58.5M loss from continuing ops a year earlierstevewagsinvest.com. Operating expenses fell year-on-year as biosimilar-related spending wound down and the company focused on core immunotherapy activitiesstevewagsinvest.com.
Current Financial Position: Coherus’s balance sheet was dramatically strengthened in H1 2025. After the Udenyca sale closed, Coherus received $483.4 million in cash (plus potential milestones)stevewagsinvest.com. It immediately retired virtually all debt – by Q2 2025, the company announced it had paid off $230M of outstanding debt (including the remaining Pharmakon term loan)intaspharma.com. As a result, Coherus now has a net cash position that likely exceeds its market capitalization. Cash and equivalents at end of 2023 were only $117.7Msec.gov, but pro forma for the asset sales, cash should be in the mid-nine figures (e.g. $400M+ after debt payoff). This war chest is earmarked to fund ongoing trials and launches. The downside of Coherus’s transformation is that near-term earnings will be poor: with minimal revenue and continued high R&D, net losses will persist in 2024–2025. The company does not currently generate positive EBITDA and will rely on its cash reserves to sustain operations until (if) pipeline products reach market.
Valuation Multiples: Traditional valuation metrics are in flux given the corporate changes. Trailing P/E is not meaningful (2024–25 earnings are negative). EV/Revenue has become extremely low: at a recent share price of around $1.20 (Aug 2025) the market cap is roughly $120–130 million, which is below the company’s cash on hand. Adjusting for an estimated ~$400M net cash, Coherus’s enterprise value is negative – implying the market assigns little or no value to its ongoing business, a sign of skepticism about future revenues. On a simpler metric, Coherus traded at ~0.5× Price/Sales relative to 2023 revenues of $257M, far cheaper than the biotech industry average (typically several times sales) – again reflecting that those sales came from now-divested assets. A more relevant multiple looking forward is Price-to-book or cash: with so much cash post-divestiture, Coherus is valued at a fraction of book value (for instance, price-to-cash <0.3×, indicating a steep discount). By end of Q2 2025, Coherus had essentially no debt and hundreds of millions in cash, yet a market cap near $120Mstocktitan.net. This disconnect suggests investors doubt Coherus’s ability to turn that cash into profitable products, pricing in aggressive cash burn and/or future dilution. For a speculative biotech like Coherus, valuation now hinges on pipeline potential rather than earnings multiples. Sell-side analysts remain cautiously optimistic – the consensus 12-month price target is around $4–5 (implying ~3–4× upside from current levels)global.morningstar.comstockanalysis.com, which likely assumes moderate success of toripalimab and pipeline by 2025–2026. Overall, Coherus’s valuation is low by asset metrics (making it appear undervalued based on cash and past sales) but high by profitability metrics (since it has none). This bifurcation will resolve as the company either builds new revenue streams (justifying a higher valuation) or continues burning cash (in which case the low market cap may prove warranted).
Investing in Coherus entails substantial risks, befitting a company in mid-transition with heavy reliance on future R&D success. Major risk factors include:
Pipeline Clinical and Regulatory Risk: Coherus’s growth plan is essentially a bet on its pipeline. The lead candidates (CHS-114, IL-27 antibody, etc.) are only in Phase 1/2. There is significant uncertainty whether these trials will demonstrate sufficient efficacy and safety to advance to approval. Failure of one or more key studies would leave Coherus with little to drive revenue beyond Loqtorzi’s niche sales. Even if the science is sound, regulatory hurdles (trial design, FDA requirements) could delay or derail approvals. The company has already incurred large expenses licensing these assets (e.g. paying Junshi Biosciences $35M for optionssec.gov), which will be for naught if approvals aren’t achieved.
Commercial and Competitive Risk: In NPC, toripalimab enjoys a unique position now, but competition could encroach. Merck’s Keytruda (pembrolizumab) and other PD-1 inhibitors are not approved for NPC, but clinicians might use them off-label or new trials could be run by competitors. If a larger pharma obtained approval in NPC (or if NPC patient volumes remain very low), Loqtorzi’s revenue could underwhelm. More broadly, Coherus aims to expand toripalimab or combos into cancers like head & neck, lung, liver – highly competitive markets dominated by entrenched players (Merck, BMS, Roche). For example, any attempt to penetrate non-small cell lung cancer with a toripalimab-based regimen faces Keytruda’s near-total market share and numerous combo trials from big pharma. Coherus’s small size means it will be competing against far larger R&D budgets and commercial forces. In short, market share gains are uncertain: Coherus might end up an also-ran if its combos don’t show clear differentiation. Its remaining biosimilar (Yusimry for Humira) also confronts intense competition – with over 10 Humira biosimilars on the U.S. market in 2023, Coherus had minimal penetration and has essentially removed this from its core operationsstevewagsinvest.com. Competition drives pricing pressure too: any revenues Coherus generates (biosimilar or novel) could come at lower margins if discounting is needed to win adoption.
Funding and Cash Burn Risk: While Coherus bolstered its cash via asset sales, it also lost the cash flow those products provided. The company now must finance its clinical programs and operating costs out of its cash reserves. Its annual operating burn (post cost cuts) is guided around $250–265M in 2024sec.gov. With ~$480M new cash from Udenyca’s sale, plus ~$100M existing, Coherus likely has 2–3 years of runway at current burn rates. However, as it advances multiple Phase 2 and potential Phase 3 trials concurrently, R&D spending could rise again. There is a risk that by 2026–2027 Coherus will need to raise capital (via equity dilution or partnering deals) if pipeline progress doesn’t generate revenue by then. In a higher interest rate environment, capital is costly: equity raises at the current low stock price would be severely dilutive to shareholders. Thus, the company’s very ability to continue its mission in the long run may require careful cash management or successful milestone achievements (e.g. the up to $75M in Udenyca sale milestones that could come if certain sales targets are met by the buyerstevewagsinvest.com).
Execution Risk: Coherus is essentially rebuilding its business. There are execution challenges in shifting from a biosimilar sales model to an innovative biotech. Developing and marketing novel immunotherapies demands different capabilities (e.g. clinical trial execution, educating specialists on new mechanisms) as opposed to selling cost-saving biosimilars. The management must execute clinical development flawlessly and also ramp up a U.S. oncology salesforce for Loqtorzi (albeit on a small scale for NPC). Any missteps – trial delays, manufacturing issues (biologics manufacturing is complex; Coherus had a supply interruption in late 2024 with Udenycastevewagsinvest.com), or slow uptake of Loqtorzi – could compound financial pressures. Furthermore, Coherus’s strategy to focus and cut costs could risk under-investing in commercial support just when launching a new drug, which might hurt Loqtorzi’s trajectory if not carefully balanced.
Macroeconomic and Policy Factors: Broader trends in healthcare and the economy can impact Coherus. For instance, the U.S. Inflation Reduction Act (IRA) has provisions that will allow Medicare to negotiate prices on certain drugs; while Loqtorzi is new and likely exempt for several years, any pipeline drug that becomes a big seller could face pricing pressure down the line once eligible. Conversely, policies encouraging biosimilars (like interchangeability guidelines) once benefitted Coherus’s old business; now, as an innovator, Coherus faces pricing scrutiny rather than tailwinds. Economic conditions also matter: high inflation and interest rates increase the cost of running trials and raise the hurdle for biotech financing. Investor risk aversion in a rising-rate environment has particularly hurt small-cap biotech valuations, as seen by Coherus’s extremely low market cap relative to its assets. On the positive side, oncology demand is relatively insulated from typical economic cycles – cancer treatments are priority expenditures, so a recession would not drastically cut demand for Coherus’s products. However, market volatility can affect Coherus’s stock and its ability to raise money. Additionally, currency and geopolitical issues could affect Coherus’s partnerships (notably, its key partner Junshi is based in China – U.S./China trade or regulatory frictions could complicate the supply or development of toripalimab).
In sum, Coherus faces a high-risk, high-reward profile. The greatest risks stem from clinical uncertainty and competitive pressure, which could prevent the company from ever generating sufficient revenue to justify its expenditures. Financial and execution risks further heighten the challenge during this transformation period. Investors must also consider that Coherus has essentially “bet the farm” on immuno-oncology – a field where many larger companies have stumbled – and thus the probability of setbacks is significant. The macro backdrop (rising rates, regulatory changes) adds another layer of uncertainty. Mitigating factors include Coherus’s strong cash buffer (reducing near-term insolvency risk) and a reduced debt load, which give it some resilience against external shocks. Nonetheless, the overall risk level is very high, and only investors comfortable with potential capital loss and volatility should consider an investment at this stage.
We project three realistic scenarios for Coherus’s total return over a 5-year horizon (to 2030), driven by fundamental outcomes. Rather than anchoring to the current ~$1.20 share price, these scenarios are built from the ground up – considering the company’s product success or failure and applying appropriate valuations in each case. We also integrate any non-core asset values (e.g. remaining cash or milestone payments) into the valuation. Below are the High, Base, and Low cases, each with key drivers, projected 5-year share price, a notional price trajectory, and probability weightings. (Note: All share prices are on a post-transaction basis; Coherus did not reverse-split as of 2025, but if it does in future, prices would adjust accordingly.)
(“Boom or Bust” scenario – here, the “Boom”)
Fundamental Drivers: In the high scenario, Coherus successfully transitions into a prominent immuno-oncology player. Loqtorzi (toripalimab) gains traction beyond NPC: by 2027 it secures FDA approval in at least one additional indication (e.g. second-line head & neck cancer) based on positive combo trial data with CHS-114 (CCR8 antibody). Sales of Loqtorzi ramp up to ~$150M/year by 2030, in line with management’s peak aspirationsquantisnow.com, as NPC adoption saturates and new indications contribute incremental revenue. The pipeline delivers a win: CHS-114, for example, demonstrates significant efficacy in combination with PD-1, leading to a Phase 3 success and approval by 2029 in a tumor like refractory gastric cancer or head & neck SCC. Similarly, casdozokitug (IL-27 antibody) shows compelling Phase 2 results in hepatocellular carcinoma (liver cancer), and is fast-tracked in combination with toripalimab, reaching the market around 2030. In this bull case, Coherus effectively has two or more marketed novel therapies (toripalimab and at least one new immunotherapy) addressing sizeable cancer populations. This drives a steep revenue inflection: by 2030 total revenues could exceed $500 million, comprised of Loqtorzi (NPC + new uses) and new combo therapy sales. Importantly, Coherus’s earlier sacrifices pay off – the $400M+ in cash is efficiently used to fund trials without diluting shareholders, and by 2028 the company achieves breakeven and turns profitable as high-margin oncology drug sales ramp up. Non-core contributions: In this rosy scenario, Coherus likely also collects the full $75M in Udenyca sale milestones from Intas by 2027 (implying Udenyca sales exceeded targets under Intas). Additionally, Coherus might monetize Yusimry (Humira biosimilar) via an out-licensing – perhaps receiving a modest lump sum or royalties if a partner markets it – but this is minor (say, <$25M value) and not central to valuation. The main “asset” outside operations is still cash: even after pipeline investments, Coherus might retain a net cash buffer of ~$100M in 2030 in this scenario (since it did not need emergency financing).
5-Year Share Price Projection: We estimate that under these bullish fundamentals, Coherus’s stock would be valued akin to a mid-cap oncology biotech. By 2030, with >$500M revenues and growth outlook, a price-to-sales multiple of ~4× or P/E in the 15–20× range (on expected earnings) is plausible given the company’s demonstrated ability to create successful drugs. This implies a market cap in the ~$2–3 billion range. Assuming share count remains around ~100 million (no major dilution), share price could reach ~$20–30 at the 5-year mark. To be conservative, we’ll take the lower end: $20/share in 5 years. This represents a dramatic increase (reflecting the “boom” outcome). The path to $20 would likely not be linear – the stock might climb as trial results and approvals materialize. An illustrative trajectory: perhaps reaching mid-single digits ($5–6) in 2026 if Phase 2 data are positive, jumping to low teens on a pivotal trial success in 2027–28, and hitting ~$20 by 2030 as product sales flourish. A potential share price trajectory under the High Case is shown below:
| Year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 (Proj.) |
|---|---|---|---|---|---|---|
| High Case Price | $1.5 – $2.0 | $4 | $8 | $12 | $16 | $20 |
Table: High Case share price trajectory (approximate)
Probability Weight: We assign a 20% probability to the High Case. This reflects that several things must go right – a hit rate that is optimistic given industry norms (many novel agents fail in Phase 2/3). Nonetheless, Coherus has multiple “shots on goal” in its pipeline and the cash to pursue them, so a one-in-five chance of major success is not unreasonable.
(Steady outcome; neither breakout nor breakdown)
Fundamental Drivers: In the base scenario, Coherus achieves partial success. Loqtorzi remains the cornerstone: it grows steadily in NPC, capturing virtually all eligible patients, but NPC being a small indication translates to perhaps $40–60M/year peak sales by 2028 (near the low end of guidance). The drug does not gain approval in big new indications – perhaps a Phase 3 in broader head & neck cancer fails to beat Keytruda, limiting toripalimab’s use mostly to NPC and some off-label niche uses. On the pipeline, assume mixed results: one of the two lead assets (either CHS-114 or casdozokitug) shows promising efficacy signals and advances, but the other disappoints or faces delays. For example, CHS-114 might demonstrate moderate benefit in combination therapy by 2026 and move into Phase 3, but as of 2030 no approval yet (still in trials). Casdozokitug might show only incremental benefit in HCC, leading the company to pause that program. Coherus may introduce a new preclinical candidate (like ILT4-targeted CHS-1000, which IND was planned in 2024sec.gov), but it remains in early-stage by 2030. Essentially, Coherus survives and makes progress, but does not have a second approved product by 5 years. Revenues in 2030 would thus be relatively modest – dominated by Loqtorzi’s ~$50M and perhaps some remaining biosimilar revenue if Coherus retains a tail of Yusimry sales or royalties (e.g. maybe $10–20M/year in the Humira biosimilar market if partnered). Total revenue might be on the order of $70–100 million in 2030. The company’s cash burn slows as it finishes some trials; it uses up a good chunk of its cash but avoids bankruptcy, potentially partnering one asset to bring in some cash. By 2030, Coherus might still have, say, ~$50M cash left (plus any milestone from Udenyca sale – assume Intas hits at least one milestone, giving Coherus ~$25M of the $75M by 2027). Profitability is not achieved in this scenario; the company continues to run at a manageable loss or roughly breakeven by 2030, depending on how much it has cut R&D by then.
5-Year Share Price Projection: In the base case, Coherus in 5 years is a small but viable oncology niche player, with one marketed product and a pipeline in late-stage development (but unproven). The valuation would likely reflect Loqtorzi’s limited cash flows plus some option value for the pipeline. A reasonable outcome might be a market cap of a few hundred million. For example, at 2030 one could value Loqtorzi’s $50M revenue at maybe 2× sales ($100M) given its slow growth, add, say, $150M for pipeline prospects (if one Phase 3 ongoing, investors still assign some hope value), and whatever cash remains ($50M). That sums to ~$300M market cap. With ~100M shares, that is about $3.00 per share. We choose $4.00/share as a base-case 5-year price target to allow some upside if the pipeline’s promise is appreciated (and to align with the notion that current market price is very depressed). $4 in 2030 would be a moderate success – roughly quadrupling from today, but far below the highs Coherus once traded at. The share price trajectory here might be relatively flat for a few years and only improve if pipeline news is encouraging: for instance, the stock might hover around $1–2 in 2025–26, rise toward $3–4 if a Phase 3 trial is initiated by 2027, and end around $4 by 2030 if the company is still intact and on the cusp of something. We illustrate a possible path:
| Year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 (Proj.) |
|---|---|---|---|---|---|---|
| Base Case Price | $1.0 – $1.5 | $1.5 | $2.0 | $3.0 | $3.5 | $4.0 |
Table: Base Case share price trajectory (approximate)
Probability Weight: We assign the highest probability, 50%, to the Base Case. This reflects the view that Coherus will likely muddle through – neither hitting a grand slam nor collapsing. The base case assumes the company’s existing assets provide enough value to justify a higher price than today (which primarily prices in failure), but not so much as to reach double-digit stock levels. It’s essentially the “middle-of-the-road” expectation given current information.
(“Boom or Bust” scenario – here, the “Bust”)
Fundamental Drivers: In the low scenario, Coherus’s bold pivot fails to create value. Loqtorzi underperforms – perhaps NPC patient uptake is slow (due to difficulties identifying patients or competing off-label regimens), yielding only ~$20–30M annual sales at peak. Any attempts to broaden toripalimab’s label stumble: larger trials do not meet endpoints against entrenched competitors, so no new approvals are obtained. The pipeline disappoints as well: for instance, by 2026, early trials of CHS-114 and IL-27 show either lackluster efficacy or unexpected safety issues, causing Coherus to halt one program and struggle to find partners. Without clear winners in the clinic, Coherus faces tough choices – it may continue one program (burning cash) but has no guarantee of success by 2030. Essentially, no new product reaches market in this timeframe. The company’s revenue by 2030 would then be minimal: just Loqtorzi’s small sales (perhaps declining if other treatments encroach on NPC) and maybe a trivial amount of residual Yusimry sales (if any). We could be looking at <$50M/year revenue or even < $20M if toripalimab fails to gain traction. Meanwhile, cash burn continues unabated: management likely pours money into trials hoping for a hit, and by around 2027 the cash from asset sales is largely exhausted. If the stock remains very low, raising equity is not practical; Coherus might resort to debt financing or, worse, cut R&D drastically to avoid running out of cash. In a really dire version of this scenario, Coherus could approach insolvency by 2028 – it might be forced to sell off remaining assets (perhaps selling toripalimab rights to a larger pharma at a firesale price, or liquidating whatever IP it has). Shareholders in this scenario are heavily diluted or see the value of their holdings dwindle. Even if outright bankruptcy is avoided (noting Coherus has no debt now, so it wouldn’t default, but it could reach a point where it ceases meaningful operations), the intrinsic value left for equity could be near-zero.
5-Year Share Price Projection: In the low case, Coherus’s share price could languish well below current levels or even be effectively worthless. A potential outcome by 2030: the stock trades as a penny stock (or could be delisted from Nasdaq if it can’t maintain >$1 – perhaps it does a reverse split to stay listed, but that doesn’t change real value). We estimate ~$0.50 per share or less in 5 years for the low scenario. This might represent basically the remaining cash value (if any) divided by shares after the company winds down most operations. For example, if Coherus in 2030 has, say, $30M cash left and no prospects, and still ~100M shares, that’s $0.30/share in liquidation value. We’ll use $0.50 as a round number for scenario modeling – essentially implying an almost total loss (-60% from current ~$1.20 price). The trajectory in this scenario likely involves further decline: the stock could drift under $1 in 2025 and struggle, potentially bouncing occasionally on rumors but trending downward as trial news disappoints. By 2027–2028, if cash concerns mount, shares could fall under $0.50. There is also the possibility of abrupt moves if the company pursues strategic alternatives (e.g. selling itself) – but in a low scenario, any sale might be at a token price relative to hopes. A hypothetical price path:
| Year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 (Proj.) |
|---|---|---|---|---|---|---|
| Low Case Price | ~$1.00 | $0.75 | $0.50 | $0.30 | $0.40 | $0.50 |
Table: Low Case share price trajectory (approximate, assumes no reverse split for comparison)
Probability Weight: We assign a 30% probability to the Low Case. Given the high-risk nature of Coherus’s pipeline and the historical fact that many small biotechs fail to ever generate positive returns, there is a substantial chance that Coherus’s pivot does not succeed. In fact, the current market pricing (EV negative, stock ~$1) suggests the market assigns a high chance to a “failure” scenario. Our 30% weighting reflects that while management has put the company in a do-or-die position, it still has enough cash and one approved product to perhaps avoid total collapse – but the risk of severe value erosion is material.
Combining these scenarios and weights, we can compute an expected value for Coherus in 5 years. Using our estimates: High ($20) @ 20%, Base ($4) @ 50%, Low ($0.5) @ 30% yields a probability-weighted 5-year price of approximately $4.6. This suggests that, on a risk-adjusted basis, Coherus might be worth around $4–5/share in five years, which interestingly aligns with current analyst targets in the mid-$4 rangeglobal.morningstar.com. It implies a substantial potential upside from today’s price, but heavily contingent on avoiding the low scenario.
In summary, Coherus’s fate appears binary – either it will boom as a successful oncology innovator or bust after burning through its war chest – with a middle outcome of modest success also plausible. The probability-weighted outcome still leans positive, reflecting the asymmetry if things go right. For now, however, investors are betting on a “Boom or Bust” story. 【Boom or Bust】
To systematically evaluate Coherus, we rate key qualitative factors on a 1–10 scale, with a brief rationale for each. We then provide an overall blended score and summary.
Management Alignment – Score: 4/10. Coherus’s management and board have limited equity ownership, reducing alignment with common shareholders. Insiders hold only about 1% of sharestipranks.comfinance.yahoo.com, and while CEO Dennis Lanfear has been with the company since inception (15+ years), his stake (~1.0% of sharesfinance.yahoo.com) is relatively small. Compensation appears generous (CEO total pay ~$4.8M in the most recent year)simplywall.st with heavy stock-based awards (the company included ~$40M stock comp in 2024 expense guidance)sec.gov, but the incentives may not be tightly linked to shareholder returns. We have not seen significant insider buying despite the depressed stock price – in fact, recent filings show an insider sold ~100k shares in May 2025 at ~$0.74nasdaq.com, possibly upon leaving the company. This hints that insiders might not be doubling down at lows. On a positive note, management did take bold action to refocus and pay down debt, which could align long-term interests. But overall, the low insider ownership and absence of notable open-market buying keeps our score modest. Stronger alignment (e.g. insider purchases, higher ownership or performance-based stock vesting) would be needed to improve this score.
Revenue Quality – Score: 3/10. The quality and durability of Coherus’s revenue are currently poor. The company’s historical revenue was concentrated in two products (Udenyca and Cimerli) which have now been sold off – essentially, Coherus “turned off” its main revenue streams in exchange for one-time cash. The ongoing revenue is extremely dependent on a single product (Loqtorzi) in a small indication. This lack of diversification and scale is concerning. Moreover, Loqtorzi’s revenues are not yet proven to be recurrent at a large scale – they will depend on continual uptake of a specialty drug and could be volatile (e.g. sensitive to quarterly ordering patterns at a small number of cancer centers). Coherus has no high-margin recurring revenue like royalties or long-term contracts; it is all product sales that must be won prescribing decision by decision. The fact that Udenyca sales had to be classified as “discontinued ops” in Q1 2025stevewagsinvest.com underscores how transient previous revenues were. On the positive side, Loqtorzi’s revenue (being a therapeutic for a chronic cancer condition in many cases) could be somewhat steady once patients are on therapy, and the drug’s NCCN guideline backing may help sustain demandsec.gov. However, until Coherus builds a broader portfolio or at least expands Loqtorzi’s uses, revenue quality remains low – it’s highly concentrated and uncertain.
Market Position – Score: 5/10. This is a bifurcated story: in its chosen niche, Coherus is strong; in the broader market, it is weak. On one hand, Coherus dominates the NPC immunotherapy market by default, as Loqtorzi is the only approved agent for nasopharyngeal carcinomasec.gov. This gives it essentially 100% share of that segment, a enviable position (albeit a tiny segment). Also, Coherus proved adept at capturing share in biosimilars: Udenyca at one point held ~26% of the U.S. pegfilgrastim marketsec.gov, showing management can execute in competitive markets. On the other hand, the company’s overall market position in oncology is very limited – it is a small-cap competing with giants. In the lucrative PD-1/PD-L1 space, Coherus/Toripalimab are late entrants and must battle established drugs for any new indications (with no guarantee of success). In 2023, Coherus lost ground in its prior markets: Udenyca’s share eroded as newer competitors (Fulphila, Ziextenzo, etc.) launched, and Cimerli, despite being best-in-class, was sold off – arguably because Sandoz (a larger player) was better positioned to market it long-term. Thus, Coherus voluntarily ceded positions in two markets. In immunology (Humira biosimilars), Coherus’s Yusimry was also a minor player among many – a reason they have effectively removed it from their core operationsstevewagsinvest.com. Considering these factors, we average to a middle score. Coherus has carved out a winning position in one segment (NPC) and retains the commercial relationships in oncology clinics, but it is otherwise in a challenger position with uphill battles in bigger markets. Market share gains beyond its niche are uncertain. We’ll call the market position mixed – strong in a sliver, weak overall.
Growth Outlook – Score: 6/10. Coherus’s growth prospects are highly uncertain, but there is a plausible path to growth which warrants a slightly above-midpoint score. Having shed slow-or-declining biosimilar products, the only way from here is up – or zero. The optimistic view: starting from ~$7M in quarterly sales (Q1 2025)stevewagsinvest.com, Coherus could multiply revenue several-fold if Loqtorzi achieves even moderate penetration of NPC and perhaps other uses. Management’s 2025 Loqtorzi revenue goal of $40–50Mquantisnow.com, if met, would be ~5–6× the annualized Q1 run-rate – indicating significant near-term growth (though from a low base). Longer term, the pipeline provides avenues for exponential growth: any new approval in a larger cancer could dramatically boost revenue. For example, if an IL-27 or CCR8 therapy eventually succeeds, Coherus could see biotech-like explosive growth in years 4–5. However, the reason this doesn’t score higher is the equally real possibility of no growth or decline. If Loqtorzi stalls and no new products come, Coherus’s revenues could flatline or even shrink (as initial pent-up NPC demand is satisfied). The company essentially restarted at near-zero sales in 2024/25; whether it grows at a 50% CAGR from here or goes to zero is unclear. Given that one can rationalize scenarios of both high growth and no growth, we land slightly positive at 6/10, leaning on the notion that the pipeline and new focus give it a better shot at growth than a typical company its size. It’s worth noting that Coherus’s historical 5-year revenue CAGR (2018–2023) was volatile – rapid growth initially from Udenyca, then stagnation/decline as competition hit – which underscores that future growth will depend entirely on new products.
Financial Health – Score: 7/10. In the near term, Coherus’s financial position is quite healthy for a company of its profile. The asset sales yielded a substantial cash reserve (nearly half a billion dollars) and the company aggressively paid down debtsec.gov, leaving only a small residual $75M term loan by Q2 2024 and reportedly clearing that entirely by mid-2025intaspharma.com. Therefore, Coherus has no net debt and a cash runway of a couple years even under heavy spending. This is a stronger balance sheet than many small biotechs that often carry debt or are running on <12 months cash. Additionally, Coherus reduced its operating cost base, trimming headcount 30% to save ~$25M/yearsec.gov, which improves financial sustainability. The score is tempered by the fact that the company is still burning money (nearly $50M loss in a single quarter of 2025stevewagsinvest.com) – so its financial health will diminish over time if losses continue. However, relative to risk, Coherus has given itself a lifeline by monetizing assets. It also has the flexibility to cut more costs if needed (e.g. if pipeline fails, they can downsize further to extend runway). Another consideration: with the stock so low, equity financing is not attractive, but Coherus might not need to tap equity markets until 2026 or later. The company’s financial health thus scores well now. The reason it’s not higher than 7 is the ticking clock of cash burn and the absence of recurring cash inflows – meaning today’s healthy balance sheet could erode. But for now, Coherus is financially solvent and de-risked from a liquidity perspective, a relative strong point.
Business Viability – Score: 5/10. By “business viability” we consider the likelihood that Coherus can sustain its operations and remain a going concern in the long run. This is truly a coin flip. The company has reinvented itself around a speculative pipeline, so viability will depend on clinical success. There is a plausible path to viability: Coherus’s immunotherapy strategy could yield sufficient products to turn profitable before the cash runs out, securing its future. It has already shown adaptability (pivoting business models) which is a positive for survival. Additionally, Coherus could be an acquisition target if its pipeline shows promise – a buyout by a larger biotech could ensure its programs survive even if Coherus as an independent entity doesn’t, which from a shareholder perspective is a form of “business viability” (value realization). On the flip side, the risk of failure is very real. The company essentially has ~3 years (as per cash runway) to prove something; if not, it could face dissolution. Unlike some biotechs that have platform technologies or diversified pipelines, Coherus’s fate rests on a relatively narrow set of immuno-oncology bets in a crowded field – this raises existential risk. Weighing these, we give a neutral 5/10. Coherus is not at immediate risk of collapse (thanks to its cash), but the medium-term viability is unproven. It’s basically a race against time and trial outcomes. Future viability might also depend on management’s decisions around partnering (selling a portion of future rights to get cash could enhance viability at cost of upside). In conclusion, Coherus is viable for now, but the jury is out on whether it can reach a self-sustaining model.
Capital Allocation – Score: 4/10. Coherus’s track record on capital allocation is mixed and leans negative from the shareholder value perspective. On one hand, management deserves credit for decisive moves like selling Cimerli and Udenyca at what appear to be reasonable prices (together over $650M gross)stevewagsinvest.comsec.gov, then using proceeds to pay down high-interest debt – these actions improved the balance sheet and focused the business, which is good capital allocation in principle. However, one must weigh that against the loss of stable cash-generating assets. Essentially, Coherus sold the family silver to fund a moonshot. If the new venture fails, one could argue that capital was misallocated – turning tangible assets into R&D spending that yields no return. Historically, Coherus also made some expensive bets: e.g. acquiring Surface Oncology (to get IL-27 asset) and licensing deals with Junshi. These deals involved upfront payments (Surface acquisition, Junshi option $35Msec.gov, toripalimab milestones, etc.) that have yet to show ROI. The large operating expenses in 2021–2023 included heavy marketing for new launches (like Cimerli) only for Coherus to sell that business soon after – arguably a wasted investment in building a salesforce which was then transferred to Sandoz. Coherus also executed share issuances (ATM and public offering raising over $60M in 2022)sec.govsec.gov when its stock price was higher, which was prudent, but those funds were largely consumed in operations. The company has not returned any capital to shareholders (no dividends, no buybacks – except possibly minimal repurchases under past authorizations). To its credit, Coherus refrained from issuing dilutive equity at rock-bottom prices in 2023–25, opting instead to sell assets – a shareholder-friendly choice in that context. Still, from an investor viewpoint, capital allocation has not created shareholder value historically – the stock is down ~90% from five years ago. Much of the capital was allocated to R&D or acquisitions that haven’t paid off (yet). We give 4/10, reflecting concern that management might over-invest in long-shot projects or be late to cut losses if needed. If pipeline success comes, hindsight may view the allocation as brilliant, but currently it’s seen as risky and value-destructive until proven otherwise.
Analyst/Investor Sentiment – Score: 6/10. Sentiment around Coherus is cautiously optimistic among analysts, but very pessimistic in the market (as evidenced by the low stock price). On the sell-side, the company still garners “Buy” or “Outperform” ratings from several analysts, with price targets that are multiples of the current pricestockanalysis.com. For instance, at least one firm had a $11–12 target in 2023, and others in 2024/25 have targets in the $4–5 range – implying significant upsidequantisnow.com. The consensus seems to be that Coherus’s pipeline is undervalued, hence a generally positive bias in coverage. However, there have been notable downgrades: in mid-2024 UBS cut the rating to Neutral and slashed the target from $4 to $1.50quantisnow.com, signaling a segment of the analyst community losing confidence. Some analysts who were bullish (Maxim, etc.) moved to hold when the company pivoted, likely taking a “wait and see” stance. Among investors at large (especially retail or generalist investors), sentiment is very low – the stock’s plunge under $1 suggests many have written it off. Short interest isn’t exceptionally high (likely because the market cap is so small now), but there is certainly skepticism. The fact that Coherus has rebranded to “Coherus Oncology” and is presenting at conferences indicates it’s trying to tell a new story; it remains to be seen if the market buys it. Taking these into account, we give a slightly positive 6/10. Analysts who cover it mostly still lean positive on potential (which is a tailwind for sentiment), but actual investor sentiment as reflected in trading is bearish. The score thus balances the upbeat analyst models versus the show-me attitude of investors. Improvement in sentiment will likely require tangible good news (trial wins or revenue surprises).
Profitability – Score: 2/10. Coherus currently is not profitable by any measure (GAAP or non-GAAP), and significant profits appear at least a couple of years away, if not further. The company lost ~$238M GAAP in 2023sec.gov and is on track for substantial losses in 2024 as well. Gross margins on its biologic products are high (biosimilars and Loqtorzi likely have 60-80% gross margins), but that is overshadowed by R&D and SG&A expenses that far exceed revenue. The net margin is deeply negative, and return on equity is correspondingly negative. We expect continued net losses through 2025–2026 given the heavy development program. There is a slim chance Coherus could reach breakeven around 2027 if Loqtorzi grows and R&D spending is reined in, but that’s speculative. Historically, Coherus did achieve a brief period of profitability around 2019 when Udenyca’s sales peaked with limited competition, but that quickly reversed as they ramped R&D. With the shift to novel drugs, high R&D is likely persistent. The reason we don’t give a rock-bottom 1/10 is that Coherus does have the infrastructure capable of supporting profitability if scale is achieved – it’s not an early pre-revenue startup, it knows how to commercialize and could theoretically turn profitable if revenue rises. However, in present reality, profitability is very poor, and any profits are at best on the distant horizon. Thus 2/10 is warranted.
Track Record (Shareholder Value Creation) – Score: 2/10. Coherus’s track record for rewarding shareholders is, unfortunately, quite poor in recent history. Despite some operational successes (getting multiple biosimilars approved and launched, generating hundreds of millions in sales), the share price today is roughly 90% lower than it was 5 years ago. Early investors have been heavily diluted and have seen the stock round-trip from ~$20+ levels down to penny-stock territory. The company’s strategic pivots, while bold, suggest that initial plans did not pan out as hoped (for example, Coherus initially promised a broad pipeline of biosimilars but ended up selling them off as margins compressed). There were periods of value creation – e.g. in 2019, Coherus delivered strong earnings from Udenyca and the stock jumped, and those who timed it could profit. But Coherus did not sustain those gains; competitive dynamics and high spending eroded the value. Moreover, Coherus has not delivered any alternative form of shareholder return (no dividends, minimal buybacks). Essentially, one might characterize Coherus’s history as one of value transfer rather than creation – it raised money from equity and debt investors, used it to develop products, sold those products to bigger companies, and spent a lot on R&D, with shareholders left holding a very volatile and declining asset. The one saving grace is that Coherus did generate real revenues (over $1B cumulative in its life) and tangibly succeeded in product development more than many biotechs ever do. If measured from inception, getting multiple drugs approved is an achievement. But from the perspective of long-term shareholders, there’s been destruction of value. Only a dramatic turnaround could change this narrative. Therefore, we assign 2/10. (It’s not 1/10 because the company did have a few bright spots and some shareholders did benefit in brief windows; but overall, the track record is disappointing.)
Overall Blended Score: Taking an average of the above scores (or a weighted impression), Coherus scores roughly 4/10 on our qualitative scorecard. This reflects a company with significant weaknesses (profitability, revenue base, track record) that is counterbalanced by a few strengths (cash position, specific niche dominance). The blended score suggests Coherus is below average in quality at present, which is consistent with its speculative status. It’s important to note that this score could improve markedly if the pipeline shows proof of concept – many metrics (growth outlook, market position, track record) would shift positively with concrete success. Conversely, failure to execute in the next 1–2 years could drag scores even lower (especially business viability). For now, Coherus can be summed up as a high-uncertainty turnaround story, with quality metrics to match. 【High Uncertainty】
Investment Thesis: Coherus BioSciences (CHRS) represents a high-stakes pivot from a shrinking biosimilar business into a potential immuno-oncology growth story. The company has taken drastic, decisive steps – divesting mature assets to amass cash, slimming down operations, and concentrating on a few innovative drug candidates. This leaves Coherus in 2025 as essentially a clinical-stage oncology biotech with a twist: it already has one approved product (toripalimab/Loqtorzi for NPC) and the commercial infrastructure to support it. The bull case is that Coherus’s established commercial foothold and hefty cash reserve will enable it to capitalize on its pipeline opportunities, leading to new drug approvals and a return to revenue growth. Key catalysts ahead include: clinical data readouts for CHS-114 (CCR8 antibody) and casdozokitug (IL-27 antagonist) expected by 2026 (management has guided to Phase 2 data in that timeframe)quantisnow.com, which, if positive, could validate Coherus’s scientific approach; regulatory milestones for Loqtorzi, such as a potential FDA filing for a new indication (e.g. 1st-line NPC combination therapy or another tumor type); and commercial performance of Loqtorzi in the next few quarters – strong uptake could exceed guidance and instill confidence that Coherus can execute in the marketplace. Additionally, strategic moves like a partnership or co-development deal could be on the table – for example, Coherus might partner one of its pipeline assets with a larger pharma to offset costs (this could bring upfront cash and external validation). An outright acquisition of Coherus is also conceivable if toripalimab or another asset proves compelling; big pharma has shown appetite for immunotherapy assets and Coherus’s $100M market cap (as of 2025) is a tiny bite for a large oncology player, especially given Coherus’s $400M cash (an acquirer would essentially be “buying $1 for 30 cents” net of cash). These upside drivers must be balanced against the risks: primarily, that none of the pipeline efforts yield a commercially viable drug. In that bear case, Coherus would gradually deplete its cash and leave shareholders with little. Other risks include the competitive landscape – even if Coherus’s science works, achieving meaningful market share in tumors like lung or liver cancer is challenging against entrenched therapies. There’s also execution risk in launching Loqtorzi (e.g. educating physicians about a new drug for a rare cancer) and scaling back up for any future product launch. The company’s ability to manage costs will be tested as well; it must spend enough on R&D to drive results but not so much as to jeopardize its financial runway.
Outlook: Overall, Coherus offers a binary-like outcome profile, which means the stock could provide substantial returns if a few things go right, or continue to languish (or worse) if the thesis doesn’t play out. At the current valuation, the market is pricing in a very pessimistic scenario, essentially valuing Coherus at less than its cash. This suggests that any tangible progress (a positive trial result, a quarterly beat on Loqtorzi sales) could lead to outsized percentage gains in the stock as sentiment shifts. Conversely, disappointing news (trial setbacks, cash burn without progress) could further erode confidence. For risk-tolerant investors, the investment thesis is that Coherus’s deep undervaluation relative to assets and the optionality of its pipeline create a favorable risk-reward skew: you are effectively getting a call option on immuno-oncology success, backed by a large cash cushion. However, it is crucial to have a long time horizon and to size the position appropriately for the high volatility likely along the way. More conservative investors might wait for proof-of-concept data before committing, even if that means paying a higher price later, to reduce downside risk.
In conclusion, Coherus is at a make-or-break juncture. The next 1–2 years will likely determine whether it transitions into a successful oncology company or fades after burning its capital. Investors should monitor upcoming trial results, management’s cash management, and any partnership/buyout signals. If Coherus executes well, the current price could in hindsight look like a bargain. If not, the stock could continue to drift. Right now, with the information available, Coherus can be summarized as a “High-Stakes Bet” – one that could handsomely reward believers, but is far from guaranteed. 【High Stakes】
From a technical standpoint, CHRS has been in a pronounced downtrend, trading well below its 200-day moving average for most of the past year. The 200-day MA is sloping downward, reflecting the long-term decline from the $2–3 range into sub-$1 territory by mid-2025. Recently, the stock showed some life: after dipping to all-time lows under $0.80 in early August, it bounced back above $1.00, suggesting a potential short-term bottom. This rebound likely coincided with broader biotech sector stabilization and possibly short-covering once the Udenyca divestiture was completed (removing some uncertainty). However, the stock remains in a fragile position – it is barely above the Nasdaq minimum bid requirement (risking a compliance issue if it closes under $1 for an extended period), and trading volumes have been moderate, indicating cautious interest. Price action around news has been telling: the announcement of the Udenyca sale in April 2025 provided only a brief boost, with gains fading as investors refocused on the core oncology challenges. Likewise, Q2 2025 earnings (released August 2025) showed a large one-time gain from the sale but ongoing losses, eliciting a muted reaction. In the very short term, CHRS appears to be in a sideways consolidation between roughly $0.90 and $1.30 as the market waits for a new catalyst. The relative strength index (RSI) has been improving from oversold levels, but there is no clear upward trend established yet. Absent any major news, the stock could continue to churn in this low zone. Short-Term Outlook: Cautious to neutral – the stock needs a catalyst (like clinical data or unusually strong Loqtorzi sales in the next earnings report) to break out of its downtrend. Otherwise, there’s risk of drift or retesting lows, especially if broader market sentiment weakens. Traders should watch the $1.40 level (near the 200-day MA) as resistance and $0.80 as key support. Until a trend reversal is confirmed, the bias remains bearish, and any rallies may be sold into. 【Bearish Bias】
View Coherus BioSciences Inc (CHRS) stock page
Loading the interactive version of this report…